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Abstract
Background: Acute cholecystitis occurs frequently in the elderly and in patients with gall stones.
Most cases of severe or recurrent cholecystitis eventually require surgery, usually laparoscopic
cholecystectomy in the Western World. It is unclear whether an initial, conservative approach with
antibiotic and symptomatic therapy followed by delayed elective surgery would result in better
morbidity and outcome than immediate surgery. At present, treatment is generally determined by
whether the patient first sees a surgeon or a gastroenterologist. We wish to investigate whether
both approaches are equivalent. The primary endpoint is the morbidity until day 75 after inclusion
into the study.
Design:  A multicenter, prospective, randomized non-blinded study to compare treatment
outcome, complications and 75-day morbidity in patients with acute cholecystitis randomized to
laparoscopic cholecystectomy within 24 hours of symptom onset or antibiotic treatment with
moxifloxacin and subsequent elective cholecystectomy. For consistency in both arms moxifloxacin,
a fluorquinolone with broad spectrum of activity and high bile concentration is used as antibiotic.
Duration: October 2006 – November 2008
Organisation/Responsibility: The trial was planned and is being conducted and analysed by the
Departments of Gastroenterology and General Surgery at the University Hospital of Heidelberg
according to the ethical, regulatory and scientific principles governing clinical research as set out in
the Declaration of Helsinki (1989) and the Good Clinical Practice guideline (GCP).
Trial Registration: ClinicalTrials.gov NCT00447304
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Background
Medical problem
Acute cholecystitis is one of the most significant acute dis-
eases in the Western World, and may be associated with
only mild pain and nausea or become a severe, life-threat-
ening illness due to complications. Acute cholecystitis is
mainly caused by gall stones, whilst cholestasis is mainly
associated with superinfection with bacteria, in general
species of enterobacteria, enterococci, bacteroides and
anaerobic streptococci [1].
The principal complication is recurrent biliary colic and
cholestasis. The latter may lead to ascending cholangitis,
and whilst this can be managed with antibiotics, other
complications can not be cured conservatively, such as
gangrenous changes, gall bladder perforation and biliary
leakage, and acute necrotic gallstone pancreatitis [2-5].
Liver abscesses and underlying incidental carcinoma have
also been reported in some cases [2,6].
The risk of developing second and subsequent episodes of
acute cholecystitis is higher than the risk of suffering an
initial episode [7,8]. Laparoscopic cholecystectomy is
therefore usually recommended, but whether this should
be performed immediately or after first giving antibiotic
treatment to allow the acute condition to subside is con-
troversial [9-12].
Immediate surgery versus conservative procedure with 
subsequent elective surgery
The approach taken is often decided by whether the
patient first sees a gastroenterologist, who favors conserv-
ative initial antibiotic therapy with later elective surgery,
or a surgeon, who favors immediate surgery.
It is still unclear which approach is better in medical and
health economic terms. The infection may not respond to
conservative treatment on one hand, on the other hand
surgical intervention while the disease is acute may
increase complications, and conversion to open surgery
may be necessary. It is unclear whether it is better to con-
duct early cholecystectomy, thereby avoiding the risk of
recurrent cholecystitis or pancreatitis.
A meta-analysis by Papi et al. (2003) including 12 pro-
spective randomized trials showed no significant differ-
ence for morbidity and mortality between immediate
surgical intervention (laparoscopic or open) and elective
surgery after the acute inflammation had subsided [13].
The numbers of patients and rates of complications were
too low to enable any conclusions to be drawn. Also, their
definition of "immediate" was between 1 and 7 days after
disease onset, while the modern standard favors laparo-
scopic surgery within 24 hours of onset [14,15].
All studies in the meta-analysis had been performed
between 1970 and 2000, and Papi concluded that new
studies in an adequate number of patients to show statis-
tical significance should be performed [13]. Two subse-
quent prospective randomized trials concerning the
appropriate timing for surgery also failed to lead to con-
clusive results, except for a slightly shorter hospital stay in
patients treated with immediate surgery [16,17].
In many centers early cholecystectomy is well established
although the evidence is not yet conclusive. To our knowl-
edge there has never been a study in which both special-
ties – gastroenterology and surgery – are equally involved.
Choice of antibiotic
Moxifloxacin (Avalox®) covers the spectrum of gram-pos-
itive, gram-negative and anaerobic bacteria usually
responsible for intra-abdominal infections [18-20]. It can
be applied orally or intravenously in a single dose of 400
mg/day, resulting in bile concentrations significantly
above the minimum inhibitory concentration [21], and
3–4 times higher than plasma concentrations [22].
A controlled double-blinded study in 379 patients in the
USA showed moxifloxacin to be at least as effective as
standard treatment by with piperacillin + tazobactam i.v.
followed by oral amoxicillin+clavulanate in complicated
intra-abdominal infections [23,24]. A European prospec-
tive randomized and controlled open-label study showed
equivalent efficacy for moxifloxacin and ceftriaxone plus
metronidazole (AIDA study) [25]. Moxifloxacin was effec-
tive and well-tolerated in both studies, with gastrointesti-
nal disorders like nausea and diarrhea being the most
frequent adverse events [26,27].
Study Design
Aim of the study
The objective of this trial is to compare the 75-day mor-
bidity of two different approaches to the treatment of
acute cholecystitis: (i) laparoscopic cholecystectomy
within 24 hours of hospital admission; and (ii) initial
antibiotic treatment with moxifloxacin followed by chole-
cystectomy in the infection-free interval (Day 7 to 45).
Organization of the study
The trial is a GCP-compliant, multicenter, prospective,
randomized non-blinded study. Patients with acute
cholecystitis meeting the inclusion criteria are rand-
omized to one of the treatment arms. The study is being
audited by members of a contract research organization
(CRO) and may be subject to government inspection. The
trial was approved by the German authorities and Ethical
committees.Trials 2007, 8:29 http://www.trialsjournal.com/content/8/1/29
Page 3 of 6
(page number not for citation purposes)
Number of patients needed
The primary aim of the study is to compare morbidity in
the two groups 75 days after enrolment. A difference in
morbidity of less than 10% is defined as equivalent. The
null-hypothesis is /ρM1 - ρM2 /> 0.1, where ρMi is the mor-
bidity rate of treatment group i. Complications are
expected in 16% of patients in each group; each group
therefore needs to enroll 273 patients to permit verifica-
tion of the null-hypothesis with an α-error of 0.05 and a
β-error at 0.15, yielding a power of 90%. Assuming a
validity rate of 85%, 322 patients are required per group,
resulting in a total patient sample of 644.
Eligibility criteria
Inclusion criteria
￿ Age ≥ 18 years
￿ Patients with acute cholecystitis with three of the follow-
ing symptoms or signs
￿ Abdominal pain in the upper right quadrant
￿ Murphy's sign
￿ Leukocytosis > 10 × 103/μl
￿ Rectal temperature > 38°C or < 36.5°C
plus
￿ Cholecystolithiasis (stones/sludge) or sonographic signs
of cholecystitis (thickening and triple layer formation of
the gall bladder wall)
￿ Immediate antibiotic therapy (400 mg Moxifloxacin i.v.
once a day)
￿ Laparoscopic cholecystectomy possible within 24 hours
after presentation of the patient
￿ Informed consent
Exclusion criteria
￿ ASA IV and V (table 1)
￿ Septic shock
￿ Perforation or abscess of the gall bladder
￿ No possibility of laparoscopic surgery
￿ Additional antibiotics needed for secondary disease
￿ Intolerance to moxifloxacin or other quinolones
￿ Pregnancy (also suspected), breast feeding
￿ Life-expectancy < 48 hours
￿ End-stage liver disease (Child-Pugh C)
￿ Psychiatric or severe neurologic disease
￿ Relevant bradycardia or other symptomatic arrhythmias
￿ Significant cardiac disease
￿ Disorder with QT prolongation
￿ Hypocalcaemia or other electrolyte disorders
￿ Earlier participation in this trial
Ethics, Study Registration and Consent
The final protocol was approved by the independent eth-
ics committee of the University of Heidelberg. The study
was registered at ClinicalTrials.gov (NCT00447304).
Patients who are scheduled for laparoscopic cholecystec-
tomy (immediate or elective) due to acute cholecystitis are
informed about the trial (laparoscopic surgery, possibility
of conversion to open surgery, other risks, benefits and
confidential handling of documented findings) and are
given the opportunity to participate at the screening visit.
Table 1: ASA-Criteria
ASA Physical Status (PS) Classification System from the American Society of Anesthesiologists
ASA PS Category Preoperative Health Status
ASA PS 1 Normal healthy patient
ASA PS 2 Patients with mild systemic disease
ASA PS 3 Patients with severe systemic disease
ASA PS 4 Patients with severe systemic disease that is a constant threat to life
ASA PS 5 Moribund patients who are not expected to survive without the operation
ASA PS 6 A declared brain-dead patient who organs are being removed for donor purposes
American Society of Anesthesiologists (ASA) Physical Status (PS) Classification System. Categories to classify the preoperative health status of 
patients.Trials 2007, 8:29 http://www.trialsjournal.com/content/8/1/29
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Informed consent is required. Patients may withdraw
from the study at any time without giving reasons and
without jeopardizing their further treatment. The investi-
gator may also withdraw patients if this is in their best
interests.
Randomisation and procedures for minimizing 
bias
This study is randomized to minimize bias. Sealed rand-
omization envelopes are provided in packs of four by the
CRO and are held centrally at each investigational site. An
envelope is opened when a patient agrees to take part and
patients are informed whether they are to be treated with
immediate surgery or initial conservative antibiotic ther-
apy.
Study treatment
Day 1 is defined as the day the patient presents to the hos-
pital. He undergoes a physical examination, vital signs are
documented, and an abdominal ultrasound investigation
is performed to confirm the diagnosis of acute cholecysti-
tis. A blood sample is also taken for standard laboratory
diagnosis (including Na, K, INR, Hb, platelets, leukocytes,
bilirubin, ALT, AST, gamma-GT, AP, amylase, lipase, urea,
creatinin and CRP). All relevant concomitant diseases
(e.g. coronary heart disease, diabetes mellitus) indicative
for morbidity and mortality are recorded [28].
The patient is informed about the trial and is given the
opportunity to participate. After the patient has given his
informed consent, he is randomized, and all baseline
findings, date of birth, age, sex, medical history, height
and weight are documented in the CRF.
All patients are examined daily while in the hospital. The
laboratory investigations are repeated on Day 3. Samples
are taken for microbiological cultures, if necessary. At Day
75 (test-of-cure visit), all diagnostic procedures and treat-
ments between Day 1 and Day 75 are documented. The
laboratory determinations and physical examination are
repeated, and vital signs are measured. Morbidity is docu-
mented according to Table 2.
Procedure for patients receiving immediate surgery
￿ Laparoscopic cholecystectomy in the 24 hours after hos-
pital admission
￿ Antibiotic therapy with moxifloxacin 400 mg i.v. once
per day for 48 hours followed by oral Moxifloxacin 400
mg daily or discontinuation of antibiotic treatment if pos-
sible
￿ Discharge of the patient as soon as possible after Day 2,
if the body temperature, CRP and leukocytes are normal
￿ Test-of-Cure visit at Day 75
Table 2: Morbidity Score
Persistent abdominal pain > 72 h 1 Pain treated by morphine or derivatives > 72 h
Persistent fever > 72 h 1 Rectal temperature > 38.5°C at least twice
Persistently raised signs of infection > 72 h 1 Persistently elevated CRP or leukocytosis
Wound-healing disorder 2 Any problem leading to re-opening of the wound with subsequent open wound treatment
Thrombosis 3 New onset of leg or pelvic thrombosis
Bleeding 3 Need for more than two bags of packed red cells during or after surgery
Cholangitis 3 New increase in AP, GGT (>2× ULN), bilirubin (>1× ULN) plus leukocytosis (> 12 × 103/μl) or 
increase in CRP (> 5× ULN)
Icterus 3 New increase in bilirubin, AP and GGT (>2× ULN)
Bile leakage 3 Persistent leakage shown by CT, MRI or ERCP
Abscess 3 Shown by CT, MRI or ultrasound
Pneumonia 3 Shown by X-ray plus drop in arterial pO2 plus clinical signs of pneumonia plus leukocytosis plus 
increased CRP
Embolic lung disease 4 Increased PA pressure (echocardiogram), TNT/TNI, D-dimers
Peritonitis 4 New occurrence of peritonitis
Pancreatitis 4 Increased pancreatic enzymes (> 3× ULN) plus new increase in CRP (> 5× ULN) plus positive 
clinical signs
Renal failure 4 Drop in urine production below 500 mL/day plus increased creatinine and urea (> 2× ULN)
Relaparotomy 5 Need for follow-up surgery
Cerebral ischemia or bleeding 5 New neurological symptoms with corresponding to changes in cerebral CT
Myocardial infarction 5 Changes in TNT/TNI with or without changes in the ECG meeting the criteria of STEMI of 
NSTEMI
Septic shock 5 Leukocytosis (> 12 × 103/μl) or leukopenia (< 4 × 103/μl) plus temperature < 36.5°C or > 
38.5°C plus clinical signs
Death 63 (Sum of all complications + 1)
Different complications and side effects that may affect the patients during the study are listed and scored differently in increasing severity. Death as 
worst outcome is scored the sum of all complications plus 1.Trials 2007, 8:29 http://www.trialsjournal.com/content/8/1/29
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Procedure for patients receiving primarily conservative 
therapy with elective surgery
￿ Therapy with i.v. moxifloxacin 400 mg once daily for 48
hours followed by oral moxifloxacin 400 mg per day. Dis-
continuation of moxifloxacin after Day 7, provided body
temperature, CRP and leukocytes are normal
￿ Discharge of the patient as soon as possible after Day 4
on oral moxifloxacin
￿ Elective cholecystectomy between Days 7 and 45 after
admission to study using single-shot moxifloxacin i.v. for
prophylaxis
￿ Test-of-Cure visit at Day 75
Primary and secondary endpoints
Primary endpoints
Primary endpoint is morbidity at the test-of-cure (TOC)
visit (75 days after trial inclusion) in the tested population
valid for efficacy.
Secondary endpoints
1. Morbidity over 75 days using the scoring system
showed in Table 2
2. Morbidity 3 days after cholecystectomy (immediate
and elective)
3. Rate of conversion from laparoscopic to open surgery
4. Change of antibiotic due to non-response or non-toler-
ation of moxifloxacin
5. Mortality at Day 75
6. Cost-efficiency
7. Hospital time
8. Safety and tolerance of moxifloxacin
9. Duration of hospital stay after cholecystectomy (days)
Adverse events and serious adverse events
Adverse events and serious adverse events and deaths
occurring up to Day 75 were recorded. An adverse event
(AE) is every medical event that worsens or impairs the
well-being of the patient not being part of the natural
course of the disease but may be due to treatment or drug
application. The term AE can cover any sign, symptom or
reaction, including not normal laboratory findings, inde-
pendent if caused by the tested procedure and medication
or not. Adverse event intensity (mild, moderate or severe)
and relationship to the treatment or the study drug moxi-
floxacin (probable, possible, unlikely or none) were cate-
gorized. Serious adverse events (SAEs) included those
events that were fatal, life-threatening, required hospitali-
zation, resulted in disability or otherwise endangered the
patient.
All AEs and SAEs will be documented in detail in the case
report form (CRF) and will be reported to the principal
investigator at regular intervals. SAEs have to be reported
within 24 hours to the principal investigator, and must be
documented separately on an SAE report form within 24
hours. According to law and guidelines, SAEs have to be
reported to the ethics committee(s) and supervisory
board(s) as necessary. The period of observation for AE
reporting is from Day 1 to Day 75.
Discussion
All statistical tests will be performed two-sided with a level
of significance of 5%. The patients will be analyzed as
treated. The principle analysis will be on evaluable
patients and a supportive intent-to-treat analysis will be
performed. Patients will be stratified according to severity
of their condition (ASA ≤ 2 vs. ASA > 2); the principle
analysis will be stratified, but a non-stratified analysis will
also be performed
The groups will be tested for equivalence of distribution of
age, sex and body mass index. The analysis will be con-
ducted using analysis of variance with the factors study
group and severity of disease, stratified by the Cochran-
Mantel-Haenszel test.
95% confidence intervals (CI) for the difference of mor-
bidity rates will be calculated. If and only if this CI lies
between -10% and +10% the two procedures will be con-
sidered equivalent. The calculation of the 95% CI will be
stratified by severity (ASA ≤ 2 vs. ASA > 2). A Breslow-Day
test will be performed to check for homogeneity between
these two strata.
Amongst the secondary variables, the mean morbidity
score in the two groups stratified by severity of disease will
be compared using the Wilcoxon rank-sum test. Where
appropriate, descriptive statistics will also be performed
for all other variables.
Study organization
All eligible patients are seen by a gastroenterologist or sur-
geon and are enrolled after giving informed consent. The
incidence of patients with acute cholecystitis ranges from
10 to >100 per year at different investigational sites. With
about 30 sites, it is estimated that enrollment of 644
patients will take about 24 months. All findings are
recorded in the patients medical records and CRF pro-
vided for this study by the investigator. Data verificationPublish with BioMed Central    and   every 
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is performed by the CRO, who will also perform the anal-
ysis on the locked database after plausibility testing and
data query correction.
Competing interests
The author(s) declare that they have no competing inter-
ests.
Authors' contributions
KW participated in the design and coordination of the
study and drafted the manuscript. JE, CG and JK partici-
pated in the design and coordination and helped to draft
the manuscript. JE and CG conceived the study. JE, CG, JK
and KW supervised the coordination of the different trial
centers. MWB and WS supervised the coordination of the
study. All authors read and approved the final version of
the manuscript.
References
1. Lubasch A, Lode H: Antibiotic therapy in cholecystitis, cholan-
gitis and pancreatitis.  Internist 2000, 41:168-174.
2. Tokunaga Y, Nakayama N, Ishikawa Y, Nishitai R, Irie A, Kaganoi J,
Ohsumi K, Higo T: Surgical risks of acute cholecystitis in eld-
erly.  Hepatogastroenterology 1997, 44:671-676.
3. Ziessman HA: Acute cholecystitis, biliary obstruction, and bil-
iary leakage.  Semin Nucl Med 2003, 33:279-296.
4. Browning JD, Horton JD: Gallstone disease and its complica-
tions.  Semin Gastrointest Dis 2003, 14:165-177.
5. Schirmer BD, Winters KL, RF E: Cholelithiasis and cholecystitis.
J Long Term Eff Med Implants 2005, 15:329-338.
6. Bakalakos EA, Melvin WS, Kirkpatrick R: Liver abscess secondary
to intrahepatic perforation of the gallbladder, presenting as
a liver mass.  Am J Gastroenterol 1996, 91:1644-1646.
7. Hoem D, Viste A, Horn A, Gislason H, Sondenaa K: Cholecystec-
tomy improves long-term success after endoscopic treat-
ment of CBD stones.  Hepatogastroenterology 2006, 53:655-659.
8. Strasberg SM, Clavien PA: Overview of therapeutic modalities
for the treatment of gallstone diseases.  Am J Surg 1993,
165:420-426.
9. Johansson M, Thune A, Blomqvist A, Nelvin L, Lundell L: Manage-
ment of acute cholecystitis in the laparoscopic era: results of
a prospective, randomized clinical trial.  J Gastrointest Surg 2003,
7(5):642-645.
10. Lo CM, Liu CL, Fan ST, Lai EC, Wong J: Prospective randomized
study of early versus delayed laparoscopic cholecystectomy
for acute cholecystitis.  Ann Surg 1998, 227(4):461-467.
11. Giger U, Michel JM, Vonlanthen R, Becker K, Kocher T, Krahenbuhl
L: Laparoscopic cholecystectomy in acute cholecystitis: indi-
cation, technique, risk and outcome.  Langenbecks Arch Surg
2005, 390:373-380.
12. Gurusamy KS, Samraj K: Early versus delayed laparoscopic
cholecystectomy for acute cholecystitis.  Cochrane Database Syst
Rev 2006, 4:CD005440-CD005440.
13. Papi C, Catarci M, D'Ambrosio l, Gili L, Koch M, Grassi GB, Capurso
L: Timing of cholecystectomy for acute calculous cholecysti-
tis: meta-analysis.  Am J Gastroenterol 2004, 99:156-157.
14. Lai PB: Randomized trial of early versus delayed laparoscopic
cholecystectomy for acute cholecystitis.  Br J Surg 1998,
85:764-767.
15. Kiviluoto T: Randomized trial of laparoscopic versus open
cholecystectomy for acute and gangrenous cholecystitis.
Lancet 1998, 351:321-325.
16. Serralta A: Prospective evaluation of emergency versus
delayed laparoscopic cholecystectomy for early cholecysti-
tis.  Surg Laparosc Endosc Percutan Tech 2003, 13:71-75.
17. Chandler CF: Prospective evaluation of early versus delayed
laparoscopic cholecystectomy for treatment of acute chole-
cystitis.  Am Surg 2000, 66:896-900.
18. Ackermann G, Schaumann R, Pless B, Claros MC, Goldstein EJC, Rod-
loff AC: Comparative activity of moxifloxacin in vitro against
obligately anaerobic bacteria.  Eur J Clin Microbiol Infect Dis 2000,
19:228-232.
19. Edmiston CE, Krepel CJ, Seabrook GR, Somberg LR, Nakeeb A, Cam-
bria RA, Towne JB: In vitro activities of moxifloxacin against
900 aerobic and anaerobic cal isolates from patients with
intra-abdominal and diabetic foot infections.  Antimicrob Agents
Chemother 2004, 48:1012-1016.
20. MacGowan AP: Moxifloxacin (Bay 12-8039): a new methoxy
quinolone antibacterial.  Expert Opin Investig Drugs 1999,
8(2):181-199.
21. Schwab D, Grauer M, Hahn EG, Mühldorfer S: Biliary secretion of
moxifloxacin in obstructive cholangitis and the non-
obstructed biliary tract.  Aliment Pharmacol Ther 2005, 22:417-422.
22. Hartmann D, Jakobs R, Riemann JF: Hepatobiliäre Kinetik von
Moxifloxacin nach intravenöser Applikation.  5 Forschungswerk-
statt Moxifloxacin 2005:Leverkusen, 23./24. Juni 2005.
23. Malangoni M: Sequential IV/PO moxifloxacin versus IV pipera-
cillin-tazobactam +- amoxicillin-clavulanate for treatment of
complicated intra-abdominal infections.  44th Interscience Con-
ference on Antimicrobial Agents and Chemotherapy, ICAAC, Washington,
USA, 30 October - 2 November 2004 2004, L-990:.
24. Malangoni MA: Randomized controlled trial of Moxifloxacin
compared with Piperacillin-Tazobactam and Amoxicillin-
Clavulanate for the treatment of complicated intra-abdomi-
nal infections.  Ann Surg 2006, 244:204-211.
25. Weiß GG, Reimnitz P, Lippert H, AIDA study and AIDA study group:
Moxifloxacin for the treatment of patients with complicated
intra-abdominal infections.  ICAAC 2006, L-1299:.
26. Kubin R: Safety update of moxifloxacin: A review of clinical
trials and worldwide postmarketing surveillance.  40th Inter-
science Conference on Antimicrobial Agents and Chemotherapy, ICAAC,
Toronto, Canada, 17-20 September 2000 2000, 820:.
27. Mandell L: Safety assessment of sequential i.v./p.o. moxi-
floxacin in the treatment of patients with community-
acquired pneumonia (CAP).  11th European Congress of Clinical
Microbiology and Infectious Diseases, ECCMID, Instanbul Turkey, 1 - 4 April
2001 2001, P863:.
28. Copeland CP: POSSUM a scaring system for surgical audit.  Br
J Surg 1991, 78:356-360.